Achille Bottiglieri
@achillebott91
Medical Oncologist, @AziendaOspAL
| former @IstTumori
| MCCR23 fellow
| Interested in Head&Neck Cancer, Neuro-Oncology, and Non-Melanoma Skin Cancer
ID:3318626200
https://www.scopus.com/authid/detail.uri?authorId=57222652250 11-06-2015 08:12:53
126 Tweets
407 Followers
2,7K Following
Such a great honor to receive this important award for our project on NMIBC. Thanks associazionepalinuro for supporting us in accademic research Giuseppe Procopio Istituto Tumori AIOM Ashish M. Kamat, MD, MBBS Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition #NMIBC
Combining RWD and genomics from liquid biopsy for ML prediction of prognosis in NSCLC at poster presentation of 2nd Italian conference on AI for oncology chaired by arsela prelaj
🎥Dr Ida Taglialatela Ida Taglialatela, Medical Oncology Dept, #Melanoma Unit Istituto Tumori, about their review
👇
Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments
🔗journals.sagepub.com/share/NAYH55M4…
#CancerResearch
And now traslational results from ARCADIA trial: phase II CABO+DURVALUMAB 2nd line mUC plus Pure Variants Hystol (neuroen, Adeno, Squamo, plasmocytoid...) #GU24
Thanks to a great GU group Andrea Necchi @RivoltiniLicia @huberveronica andrea anichini VJ Oncology
NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 ASCO #GU24 ! Markus Eckstein OncoAlert UroToday.com
Fantastic conclusion to Controversies in #genitourinary tumors Istituto Tumori
Packed with insightful discussion and plenty of interesting updates. I am grateful for the valuable takeaways, and I am looking forward to applying those insights. Thanks to everyone involved!